iSpecimen Inc. (NASDAQ:ISPC) Short Interest Update

iSpecimen Inc. (NASDAQ:ISPC) saw a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 3,073,818 shares, a growth of 227.2% from the February 26th total of 939,560 shares. Based on an average trading volume of 31,293,206 shares, the days-to-cover ratio is presently 0.1 days. Currently, 35.8% of the shares of the stock are sold short. Currently, 35.8% of the shares of the stock are sold short. Based on an average trading volume of 31,293,206 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC purchased a new position in iSpecimen Inc. (NASDAQ:ISPC) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned 0.30% of iSpecimen as of its most recent SEC filing. 13.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

iSpecimen Stock Performance

ISPC traded up $0.01 on Wednesday, hitting $0.16. 1,886,203 shares of the company were exchanged, compared to its average volume of 8,167,127. The firm has a fifty day simple moving average of $0.29 and a two-hundred day simple moving average of $0.59. iSpecimen has a 12 month low of $0.14 and a 12 month high of $3.18. The stock has a market capitalization of $1.59 million, a PE ratio of -0.02 and a beta of 1.87.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.